Multi-center Registry for CCSVI Testing and Treatment (CCSVI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Downey, California, United States, 90241
- Vascular Access Center of Downey
-
Oceanside, California, United States, 92056
- North County Radiology
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Vascular Access Care of Atlanta
-
-
New York
-
New York, New York, United States, 10022
- Columbia endovascular Associates
-
Poughkeepsie, New York, United States, 12601
- Valley Endovascular Associates
-
-
Ohio
-
Dayton, Ohio, United States, 45409
- Dayton Interventional Radiology
-
-
Utah
-
Provo, Utah, United States, 84604
- Utah Valley Interventional Associates
-
Salt Lake City, Utah, United States, 84107
- Utah Vascular Clinic
-
-
Washington
-
Seattle, Washington, United States, 14220
- Vascular Access Center of Seattle
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Referral by patients primary treating physician for suspected CCSVI
Exclusion Criteria:
Abnormal kidney function Allergy to either or both of the imaging contrast agents Pacemaker or other implantable device Ferrous metal in or on the body Claustrophobia Pregnancy
-
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
CNS draining vein abnormalities
|
catheter venous angioplasty via femoral vein approach
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Short-Form 36 (SF36) Quality of Life Instrument
Time Frame: Baseline and at 1, 6 and 12 months after treatment
|
Baseline and at 1, 6 and 12 months after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: David R Hubbard, M.D., Hubbard Foundation
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CCSVI Registry
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.